Fusion Pharm Revenue vs. Current Ratio
| FSPM Stock | USD 0.0001 0.00 0.00% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 683.6 K | Current Value 717.7 K | Quarterly Volatility 189 K |
For Fusion Pharm profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Fusion Pharm to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Fusion Pharm utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Fusion Pharm's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Fusion Pharm over time as well as its relative position and ranking within its peers.
Fusion |
Is Consumer Staples Distribution & Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Fusion Pharm Current Ratio vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Fusion Pharm's current stock value. Our valuation model uses many indicators to compare Fusion Pharm value to that of its competitors to determine the firm's financial worth. Fusion Pharm is rated # 3 in revenue category among its peers. It also is rated # 3 in current ratio category among its peers . The ratio of Revenue to Current Ratio for Fusion Pharm is about 814,242 . At this time, Fusion Pharm's Total Revenue is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Fusion Pharm by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Fusion Revenue vs. Competition
Fusion Pharm is rated # 3 in revenue category among its peers. Market size based on revenue of Consumer Staples industry is currently estimated at about 148.47 Billion. Fusion Pharm adds roughly 594,397 in revenue claiming only tiny portion of stocks in Consumer Staples industry.
Fusion Current Ratio vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Fusion Pharm |
| = | 594.4 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Fusion Pharm |
| = | 0.73 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Fusion Current Ratio Comparison
Fusion Pharm is currently under evaluation in current ratio category among its peers.
Fusion Pharm Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Fusion Pharm, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Fusion Pharm will eventually generate negative long term returns. The profitability progress is the general direction of Fusion Pharm's change in net profit over the period of time. It can combine multiple indicators of Fusion Pharm, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -9.1 K | -9.6 K | |
| Net Loss | -37.9 K | -36 K | |
| Income Before Tax | -37.9 K | -36 K | |
| Total Other Income Expense Net | -8.2 K | -7.7 K | |
| Net Loss | -37.9 K | -36 K | |
| Net Loss | -37.9 K | -36 K | |
| Change To Netincome | 59.3 K | 62.2 K |
Fusion Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Fusion Pharm. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Fusion Pharm position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Fusion Pharm's important profitability drivers and their relationship over time.
Use Fusion Pharm in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fusion Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fusion Pharm will appreciate offsetting losses from the drop in the long position's value.Fusion Pharm Pair Trading
Fusion Pharm Pair Trading Analysis
The ability to find closely correlated positions to Fusion Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fusion Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fusion Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fusion Pharm to buy it.
The correlation of Fusion Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fusion Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fusion Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fusion Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Fusion Pharm position
In addition to having Fusion Pharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run World Allocation Funds Thematic Idea Now
World Allocation Funds
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
To fully project Fusion Pharm's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Fusion Pharm at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Fusion Pharm's income statement, its balance sheet, and the statement of cash flows.